Developmental biologist Dr. Alexandra Joyner reflects on her career and talks about the new passions she looks forward to pursuing in retirement.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo Oviedo-Mori survive — and thrive — with advanced lung cancer for 15 years.

Research at MSK Our research impact Research topics Core facilities & resources ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Research at MSK Our research impact Research topics Core facilities & resources ...

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Marie-Josée Kravis Women ...